B. S. Sukovatykh, A. V. Sereditsky, A. Yu. Grigoryan, M. B. Sukovatykh, V. M. Pashkov
{"title":"Quality of life in patients after treatment of deep vein thrombosis with regional catheter thrombolysis","authors":"B. S. Sukovatykh, A. V. Sereditsky, A. Yu. Grigoryan, M. B. Sukovatykh, V. M. Pashkov","doi":"10.30629/0023-2149-2023-101-7-8-376-380","DOIUrl":null,"url":null,"abstract":"The aim of the study was to compare the quality of life in patients after treatment of deep vein thrombosis with regional catheter thrombolysis using alteplase and urokinase, and to compare the results with clinical examination data. Material and methods. The assessment of quality of life and data from a control objective examination were conducted in 32 patients with deep vein thrombosis, divided into two statistically homogeneous groups of 16 individuals each. Alteplase was used for thrombolysis in the fi rst group, while urokinase was used in the second group. The quality of life in patients was evaluated using two questionnaires: SF-36 and CIVIQ-20. The severity of venous disease was determined based on the clinical assessment of venous return impairment. Results . In the fi rst group, the physical component of health according to the SF-36 questionnaire was 56 (49.5; 56.3), the psychological component was 54 (50; 68.8), while in the second group it was 34 (33; 34) and 38 (31.3; 45) respectively. The overall health assessment according to the CIVIQ-20 questionnaire was 20 (10.8; 30) in the fi rst group and 40 (32.8; 43.8) in the second group. In the clinical examination, venous return impairment was absent or mild in 75% of patients in the fi rst group, and equally distributed between mild and severe in 50% of patients in the second group. Conclusion . Alteplase thrombolysis has a more positive impact on the quality of life in patients compared to urokinase.","PeriodicalId":17856,"journal":{"name":"Klinicheskaia meditsina","volume":"118 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinicheskaia meditsina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30629/0023-2149-2023-101-7-8-376-380","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The aim of the study was to compare the quality of life in patients after treatment of deep vein thrombosis with regional catheter thrombolysis using alteplase and urokinase, and to compare the results with clinical examination data. Material and methods. The assessment of quality of life and data from a control objective examination were conducted in 32 patients with deep vein thrombosis, divided into two statistically homogeneous groups of 16 individuals each. Alteplase was used for thrombolysis in the fi rst group, while urokinase was used in the second group. The quality of life in patients was evaluated using two questionnaires: SF-36 and CIVIQ-20. The severity of venous disease was determined based on the clinical assessment of venous return impairment. Results . In the fi rst group, the physical component of health according to the SF-36 questionnaire was 56 (49.5; 56.3), the psychological component was 54 (50; 68.8), while in the second group it was 34 (33; 34) and 38 (31.3; 45) respectively. The overall health assessment according to the CIVIQ-20 questionnaire was 20 (10.8; 30) in the fi rst group and 40 (32.8; 43.8) in the second group. In the clinical examination, venous return impairment was absent or mild in 75% of patients in the fi rst group, and equally distributed between mild and severe in 50% of patients in the second group. Conclusion . Alteplase thrombolysis has a more positive impact on the quality of life in patients compared to urokinase.